The recent biotech market downturn raised the bar for going public. Unlike the 2020-2021 period where preclinical companies IPO'd, today's successful offerings are from companies with mid-to-late-stage clinical programs. This de-risked profile is necessary to attract both specialist and crucial generalist investors back to the sector.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Neurvati's model bypasses early-stage discovery risk by requiring assets to have 'peri-proof-of-concept' data (e.g., Phase 1b/2a) in humans. This focus on clinically de-risked programs with demonstrated biological activity and safety allows them to concentrate on late-stage development and execution.

To build investor confidence in the high-risk neuroscience field, Neurocrine employs a dual strategy. It highlights its own proven track record while simultaneously de-risking its pipeline by targeting biological pathways already validated by competitors, aiming to create superior, best-in-class medicines rather than pursuing unproven science.

In the difficult CNS space, novel drugs often fail because of an inability to prove target engagement in humans. By choosing metabolic targets, Leal can use clear biomarkers from blood tests or imaging to de-risk its programs and provide early proof of efficacy to investors, clinicians, and partners.

To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.

Tortugas Neuroscience's startup strategy focuses on in-licensing new chemical entities that have already cleared Phase 1, bypassing early toxicity and IND risks. Their criteria demand that each asset be extensible to multiple indications within CNS, creating operating leverage and maximizing the chances of success.

The value of a late-stage asset is not just its scientific promise. Acquirers and investors look for a clear definition of unmet medical need, a straightforward clinical development pathway, and a well-defined regulatory landscape to de-risk the path to market.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.